Immatics Appoints Alise Reicin to Board of Directors
Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company focused on T cell-redirecting cancer immunotherapies, has appointed Alise Reicin, M.D., to its Board of Directors. Dr. Reicin, currently President and CEO of Tectonic Therapeutic, brings extensive experience in clinical development, including her role in the approval of Keytruda®. Her appointment comes as Immatics advances its pipeline of TCR-based cell therapy and bispecific product candidates.
Peter Chambré, Chairman of Immatics' Board, highlighted Dr. Reicin's expertise in facilitating the approval and launch of novel therapies. Dr. Reicin expressed enthusiasm for Immatics' potential, particularly noting the deep and durable responses from its lead cell therapy candidate, ACTengine® IMA203, in advanced metastatic melanoma patients. Her appointment continues through the Company's Annual General Meeting in 2025.
Immatics N.V. (NASDAQ: IMTX), un'azienda biofarmaceutica in fase clinica focalizzata sulle immunoterapie oncologiche con reindirizzamento delle cellule T, ha nominato Alise Reicin, M.D., nel suo Consiglio di Amministrazione. La Dr.ssa Reicin, attualmente Presidente e CEO di Tectonic Therapeutic, porta con sé una vasta esperienza nello sviluppo clinico, compreso il suo ruolo nell'approvazione di Keytruda®. La sua nomina arriva mentre Immatics avanza nel suo pipeline di terapie cellulari basate su TCR e candidati a prodotti bispecifici.
Peter Chambré, Presidente del Consiglio di Immatics, ha evidenziato l'esperienza della Dr.ssa Reicin nel facilitare l'approvazione e il lancio di terapie innovative. La Dr.ssa Reicin ha espresso entusiasmo per il potenziale di Immatics, notando in particolare le risposte profonde e durature del suo principale candidato per la terapia cellulare, ACTengine® IMA203, nei pazienti con melanoma metastatico avanzato. La sua nomina proseguirà fino all'Assemblea Generale Annuale della Società del 2025.
Immatics N.V. (NASDAQ: IMTX), una compañía biofarmacéutica en etapa clínica centrada en inmunoterapias contra el cáncer con redireccionamiento de células T, ha nombrado a Alise Reicin, M.D., en su Junta Directiva. La Dra. Reicin, actual Presidenta y CEO de Tectonic Therapeutic, aporta una amplia experiencia en desarrollo clínico, incluido su papel en la aprobación de Keytruda®. Su nombramiento llega mientras Immatics avanza en su pipeline de terapias celulares basadas en TCR y candidatos a productos bispecíficos.
Peter Chambré, Presidente de la Junta de Immatics, destacó la experiencia de la Dra. Reicin en facilitar la aprobación y el lanzamiento de terapias novedosas. La Dra. Reicin expresó entusiasmo por el potencial de Immatics, señalando en particular las respuestas profundas y duraderas de su candidato principal para terapia celular, ACTengine® IMA203, en pacientes con melanoma metastásico avanzado. Su nombramiento continuará hasta la Junta General Anual de la Compañía en 2025.
Immatics N.V. (NASDAQ: IMTX), T 세포 리디렉션 암 면역 요법에 중점을 두고 있는 임상 단계의 생명공학 회사가 Alise Reicin, M.D.를 이사회에 임명했습니다. Reicin 박사는 현재 Tectonic Therapeutic의 회장이자 CEO로서 Keytruda® 승인에 관여한 경험을 포함하여 임상 개발에 대한 폭넓은 경험을 가지고 있습니다. 그녀의 임명은 Immatics가 TCR 기반 세포 치료 및 이중 특이성 제품 후보의 파이프라인을 진행하는 가운데 이루어졌습니다.
Immatics의 이사회 의장인 Peter Chambré는 Reicin 박사의 혁신적인 치료법 승인 및 출시를 촉진하는 전문성을 강조했습니다. Reicin 박사는 Immatics의 잠재력에 대해 큰 기대를 표명하며, 특히 고급 전이성 흑색종 환자에서 주요 세포 치료 후보인 ACTengine® IMA203의 깊고 지속적인 반응을 주목했습니다. 그녀의 임명은 2025년 회사의 연례 총회까지 유효합니다.
Immatics N.V. (NASDAQ: IMTX), une entreprise biopharmaceutique en phase clinique spécialisée dans les immunothérapies anticancéreuses par redirection des cellules T, a nommé Alise Reicin, M.D. au sein de son conseil d'administration. Le Dr Reicin, actuellement présidente et PDG de Tectonic Therapeutic, apporte une vaste expérience en développement clinique, y compris son rôle dans l'approbation de Keytruda®. Sa nomination intervient alors qu'Immatics fait avancer son portefeuille de thérapies cellulaires basées sur les TCR et de candidats à des produits bispécifiques.
Peter Chambré, président du conseil d'administration d'Immatics, a souligné l'expertise du Dr Reicin dans la facilitation de l'approbation et du lancement de nouvelles thérapies. Le Dr Reicin a exprimé son enthousiasme pour le potentiel d'Immatics, notant en particulier les réponses profondes et durables de son principal candidat en thérapie cellulaire, ACTengine® IMA203, chez les patients atteints de mélanome métastatique avancé. Sa nomination se poursuit jusqu'à l'assemblée générale annuelle de la société en 2025.
Immatics N.V. (NASDAQ: IMTX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf T-Zell-umleitende Krebsimmuntherapien konzentriert, hat Alise Reicin, M.D., in seinen Vorstand berufen. Dr. Reicin, derzeit Präsidentin und CEO von Tectonic Therapeutic, bringt umfangreiche Erfahrung in der klinischen Entwicklung mit, einschließlich ihrer Rolle bei der Genehmigung von Keytruda®. Ihre Ernennung erfolgt, während Immatics seine Pipeline von TCR-basierten Zelltherapien und bispezifischen Produktkandidaten vorantreibt.
Peter Chambré, Vorsitzender des Vorstands von Immatics, hob die Expertise von Dr. Reicin bei der Ermöglichung der Genehmigung und Markteinführung neuer Therapien hervor. Dr. Reicin äußerte Begeisterung für das Potenzial von Immatics und wies insbesondere auf die tiefen und dauerhaften Reaktionen ihres Hauptkandidaten für Zelltherapien, ACTengine® IMA203, bei fortgeschrittenen metastatischen Melanompatienten hin. Ihre Ernennung gilt bis zur Hauptversammlung des Unternehmens im Jahr 2025.
- Appointment of Alise Reicin, M.D., an experienced pharmaceutical executive, to the Board of Directors
- Dr. Reicin's expertise in clinical development and drug approvals, including Keytruda®
- Advancement of TCR-based cell therapy and bispecific product candidates pipeline
- Demonstrated deep and durable responses from lead cell therapy candidate ACTengine® IMA203 in advanced metastatic melanoma patients
- None.
Houston, Texas and Tuebingen, Germany, July 31, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced the appointment of Alise Reicin, M.D., to its Board of Directors. Alise Reicin is an experienced and expert pharmaceutical industry executive and leader who has led the development of multiple important new therapies, including Keytruda®. Dr. Reicin currently serves as the President and CEO of Tectonic Therapeutic and is also a member of the Board of Directors of Sana Biotechnology. She joins Immatics’ Board of Directors as the Company advances its pipeline of novel TCR-based cell therapy and bispecific product candidates into the next phase of development.
“We are delighted to welcome Alise to the Board of Directors of Immatics. Alise has facilitated the approval and market launch of many impactful novel therapies and streamlined clinical development processes in many organizations,” said Peter Chambré, Chairman of Immatics’ Board of Directors. “Her exceptional clinical and strategic expertise will be of great value to the Board as Immatics seeks to move our TCR-based therapies for solid tumors closer to the market and to cancer patients with unmet medical need.”
“Immatics is at a dynamic stage of development, especially as the Company has demonstrated the maturation of deep and durable responses from its lead cell therapy candidate, ACTengine® IMA203, in advanced metastatic melanoma patients,” commented Alise Reicin, M.D. “I see real potential for Immatics’ two distinct TCR-based therapeutic modalities to address patients at various disease stages and with different solid tumor cancers. I look forward to working with the Board and supporting the Company as it strives to make a meaningful impact on the lives of cancer patients.”
Dr. Reicin brings extensive experience in early- and late-stage clinical development and a legacy of approved drugs in diverse therapeutic areas. Most recently, Dr. Reicin joined Tectonic Therapeutic, a company transforming the discovery of novel GPCR-targeted therapies, and, under her leadership, the company completed an
Dr. Reicin’s appointment to the Board of Directors continues through the Company’s Annual General Meeting in 2025.
- END -
About Immatics
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
Immatics intends to use its website www.immatics.com as a means of disclosing material non-public information. For regular updates you can also follow us on X, Instagram and LinkedIn.
Forward-Looking Statements
Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance. For example, statements concerning timing of data read-outs for product candidates, the timing, outcome and design of clinical trials, the nature of clinical trials (including whether such clinical trials will be registration-enabling), the timing of IND or CTA filing for pre-clinical stage product candidates, estimated market opportunities of product candidates, the Company’s focus on partnerships to advance its strategy, and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “plan”, “target”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in the Company’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company undertakes no duty to update these forward-looking statements. All the scientific and clinical data presented within this press release are – by definition prior to completion of the clinical trial and a clinical study report – preliminary in nature and subject to further quality checks including customary source data verification.
For more information, please contact:
| Media | |
| Trophic Communications | |
| Phone: +49 151 54041130 | |
| immatics@trophic.eu |
| Immatics N.V. | |
| Jordan Silverstein | |
| Head of Strategy | |
| Phone: +1 346 319-3325 | |
| InvestorRelations@immatics.com |
Attachment
FAQ
Who is the new Board member appointed by Immatics (IMTX)?
What is the significance of Alise Reicin's appointment to Immatics' Board?
What are the key developments in Immatics' (IMTX) pipeline mentioned in the announcement?
How long will Alise Reicin serve on Immatics' (IMTX) Board of Directors?
